Thursday, October 16, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Analysis

Soleno Therapeutics: A Biotech Saga of Stellar Sales and Serious Allegations

Andreas Sommer by Andreas Sommer
August 30, 2025
in Analysis, Earnings, Pharma & Biotech
0
Soleno Therapeut. Stock
0
SHARES
195
VIEWS
Share on FacebookShare on Twitter

Soleno Therapeutics finds itself at a dramatic crossroads, caught between a landmark commercial launch and a storm of allegations that threaten to derail its progress. The biopharmaceutical company’s story has rapidly evolved from a celebrated debut to a contentious legal and financial battle, leaving investors to weigh groundbreaking revenue against claims of potential fraud.

Unprecedented Market Reception for New Therapy

The launch of VYKAT XR has been nothing short of phenomenal for Soleno. The drug, which secured FDA approval in March 2025 and became commercially available in April, delivered a stunning second-quarter performance. The company reported revenue of $32.66 million, a figure that surpassed analyst expectations by a remarkable eightfold. Even the loss per share showed significant improvement, coming in at -$0.09 compared to the anticipated -$0.53.

This commercial success was driven by immediate physician and patient adoption of the treatment for hyperphagia in Prader-Willi syndrome. Treatment initiation data revealed 646 patients beginning therapy under the care of 295 distinct physicians. Furthermore, the drug’s insurance coverage extends to a patient pool exceeding 100 million lives.

Scorpion Capital’s Damning Report Triggers Selloff

The celebratory atmosphere was abruptly shattered on August 15th when activist short-selling firm Scorpion Capital released a scathing report. The analysis labeled Soleno a “one-trick pony” with an insignificant development pipeline beyond its flagship drug.

The allegations were severe: Scorpion Capital contended that VYKAT XR is not only excessively priced but may also present safety concerns for pediatric patients, citing potential hospitalizations linked to cardiac issues. Adding to these concerns, the report highlighted that the drug’s core patent protection is scheduled to expire as early as 2026.

Should investors sell immediately? Or is it worth buying Soleno Therapeut.?

Financial markets reacted instantly to the allegations. Soleno’s stock price plummeted 7.4% on the day the report was published. The fallout extended beyond the immediate selloff, with multiple law firms announcing investigations into whether Soleno Therapeutics misled investors regarding the drug’s associated risks.

Maintaining Analyst Confidence Amid Controversy

Despite the serious nature of the allegations, several prominent analysis firms have maintained their positive outlook on Soleno’s stock.

Guggenheim reaffirmed its Buy rating, attaching a $106 price target that implies a potential upside of over 50% from current levels. Similarly, HC Wainwright and Wells Fargo maintained their optimistic positions, with price targets reaching as high as $123. The consensus average price target among analysts stands at $115.

This institutional confidence appears reflected in ownership patterns, with institutional investors holding a substantial 97.4% of all shares. Several funds have significantly increased their positions in the company, though filings did show insider selling by Patricia C. Hirano, who disposed of a portion of her holdings.

The coming quarters will prove decisive for Soleno Therapeutics. The company must demonstrate whether it can convert its impressive initial sales figures into sustainable growth or whether the serious allegations will fundamentally undermine its business prospects. All eyes will be on the next earnings report for clarity.

Ad

Soleno Therapeut. Stock: Buy or Sell?! New Soleno Therapeut. Analysis from October 16 delivers the answer:

The latest Soleno Therapeut. figures speak for themselves: Urgent action needed for Soleno Therapeut. investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from October 16.

Soleno Therapeut.: Buy or sell? Read more here...

Tags: Soleno Therapeut.
Andreas Sommer

Andreas Sommer

About Andreas Sommer Over 40 years of expertise in market analysis, chart technical analysis, and strategic investment advisory. With more than four decades of experience in banking and financial journalism, Andreas Sommer is recognized as one of the leading analysts in the German-speaking market. His deep understanding of market dynamics and technical analysis has helped countless investors navigate complex financial markets.
Areas of Expertise:
  • Technical Chart Analysis
  • Strategic Investment Advisory
  • Market Trend Analysis
  • Financial Journalism
Andreas brings unparalleled insights from his extensive career in banking and financial markets, making him a trusted voice for investors seeking professional guidance.

Related Posts

Viking Therapeutics Stock
Earnings

Viking Therapeutics Stock Faces Critical Test as Earnings Approach

October 16, 2025
Trade Desk Stock
Analysis

The Trade Desk Faces Critical Test Amid Analyst Downgrade

October 16, 2025
Procter & Gamble Stock
Analysis

Procter & Gamble Shares Slide to Annual Low Despite Dividend Increase and Strong Shareholder Support

October 16, 2025
Next Post
Civista Bancshares Stock

A Tale of Two Signals: Insider Confidence Meets Analyst Caution at Civista Bancshares

IBM Stock

IBM Shares Slide Despite Strong Earnings as Software Unit Underperforms

iHeartMediaClass A Stock

iHeartMedia's Digital Growth Offsets Legacy Radio Challenges

Recommended

Groundbreaking Research Reveals Promising Treatment for OxaliplatinInduced Peripheral Neuropathy

2 years ago
MMP stock news

ETF Managers Group LLC’s New Investment in Ultragenyx Pharmaceutical Inc.: A Turning Point for the Biopharmaceutical Company’s Future

2 years ago
S&P 500 Stock

S&P 500 Futures Signal Cautious Open Following Holiday Weekend

1 month ago
GD stock news

Scotiabank Analyst Reiterates Positive Outlook on Sociedad Quimica Y Minera with Revised Price Target

2 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple Applovin BioNTech Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Lockheed Marvell Technology META Micron Microsoft MP Materials MSCI World ETF NIO Nvidia Ocugen Opendoor Oracle Oxford Lane Capital Palantir PayPal Plug Power QuantumScape Realty Income Robinhood Rocket Lab USA Salesforce Strategy Super Micro Computer Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

Beyond Meat Shares Plummet as Debt Deal Triggers Massive Dilution

S&P 500 Seeks Firmer Footing After Volatile Session

Philip Morris Bets Billions on Smoke-Free Transition Strategy

T-Mobile US: Conflicting Signals Create Investor Dilemma

Pharmaceutical Giant AbbVie Faces Critical Test Amid Acquisition and Patent Challenges

Is Exxon Mobil Stock Poised for a Breakout?

Trending

Viking Therapeutics Stock
Earnings

Viking Therapeutics Stock Faces Critical Test as Earnings Approach

by Robert Sasse
October 16, 2025
0

Shares of Viking Therapeutics are experiencing significant price swings as investors position themselves ahead of the company's...

Trade Desk Stock

The Trade Desk Faces Critical Test Amid Analyst Downgrade

October 16, 2025
Procter & Gamble Stock

Procter & Gamble Shares Slide to Annual Low Despite Dividend Increase and Strong Shareholder Support

October 16, 2025
Beyond Meat Stock

Beyond Meat Shares Plummet as Debt Deal Triggers Massive Dilution

October 16, 2025
S&P 500 Stock

S&P 500 Seeks Firmer Footing After Volatile Session

October 16, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Viking Therapeutics Stock Faces Critical Test as Earnings Approach
  • The Trade Desk Faces Critical Test Amid Analyst Downgrade
  • Procter & Gamble Shares Slide to Annual Low Despite Dividend Increase and Strong Shareholder Support

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com